Guidelines for management of high-risk African Americans with multiple cardiovascular risk factors: Recommendations of an expert consensus panel

Ethnicity and Disease

Volumn 17, Issue 2, 2007, Pages 217-220

  Williams, Richard Allen ^a   Flack, John M ^b   Gavin III, James R ^c   Schneider, Wendy R ^d   Hennekens, Charles H ^d,e,f,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d FLORIDA ATLANTIC UNIVERSITY   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f NOVA SOUTHEASTERN UNIVERSITY   (United States)

^g PH A   (United States)

Author keywords

African American; Cardiovascular disease; Multiple risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; NICOTINIC ACID; RESIN;

AFRICAN AMERICAN; ALGORITHM; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; DIABETES MELLITUS; DRUG USE; DYSLIPIDEMIA; GENDER; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE; METABOLIC SYNDROME X; PRACTICE GUIDELINE; RISK FACTOR; SITTING; UNITED STATES; WAIST HIP RATIO; CONSENSUS; FEMALE; MALE;

AFRICAN AMERICANS; CARDIOVASCULAR DISEASES; CONSENSUS; FEMALE; GUIDELINES; HUMANS; MALE; RISK FACTORS; UNITED STATES;

EID: 34447519026     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. National Vital Statistics Report. Number of deaths from 113 selected causes by age: United States, 1999 (Table 9). September 21, 2001, Vol 49, No 8. Available at: www.cdc.gov/ nchs/fastats/heart.htm. Accessed on April 18, 2002.
2. National Heart, Lung, and Blood Institute. Morbidity and Mortality Chartbook 1996. Washington, DC: US Public Health Service; May 1996.
3. Levine RS, Foster JE, Fullilove RE, et al. Black-White inequalities in mortality and life expectancy, 1933-1999: implications for Healthy People 2010. Public Health Rep. 2002;116:474-483.
4. Gavin JRIII. New classification and diagnostic criteria for diabetes mellitus. Clin Cornerstone. 1998;1:1-12.
5. Dustan HP, Rocella EJ, Garrison HH. Controlling hypertension: a research success story. Arch Intern Med. 1996;156:1926-1935.
6. Chobanian AV, Bakris GL, Black HR, et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19): 2560-2572.
7. Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
8. Williams RA. Cultural diversity in medicine. In: Williams RA ed. Humane Medicine: A New Paradigm in Medical Education and Health Care Delivery. Vol 2. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001;13.
9. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African American and White men: 16-year MRFIT findings. JAMA. 1997;277: 1293-1298.
10. Ofili EO. Managing high blood pressure and cardiovascular disease in Blacks. Assoc Black Cardiol Digest Urban Cardiol. 1995;2: 220-225.
11. Taylor HA Jr, Burchfield C, Fletcher B, et al. The Jackson Heart Study. Assoc Black Cardiol Digest Urban Cardiol. 1999;6:27-33.
12. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med. 1983;75(suppl 3A):4-11.
13. Liao Y, Cooper RS, McGhee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among Black adults. JAMA. 1995;273:1592-1597.
14. American Diabetes Association. Diabetes among African Americans. Available at: http://www.diabetes.org/main. Accessed on December 3, 2002.
15. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
16. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
17. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997; 278:313-321.
18. The Long-Term Intervention with Pravastatin in Ischemic Heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
19. Sacks FM, Pfeffer MA, Moyé LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
20. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
21. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
22. Grundy SM, Cleeman JI, Merz CN, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
23. National Heart, Lung, and Blood Institute. National Heart, Lung, and Blood Institute Obesity Education Initiative. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. June 1998. Available at: www.nhlbi.nih. gov/guidelines/obesity/e_txtbk/txgd/ algorthm/ algorthm.htm. Accessed on April 9, 2002.
24. Flegal KM, Carroll MD, Kuczmarksi RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998;22: 39-47.
25. Manson JE, Hu FB, Rich-Edwards JW, et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med. 1999; 341:650-658.
26. Peto R, Lopez AD, Boreham J, Thun M, Heath CJr, Doll R. Mortality from smoking worldwide. Br Med Bull. 1996;52:12-21.
27. LaCroix AZ, Land J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med. 1991;324: 1619-1625.
28. Fiore MC, Novotney TE, Pierce JP, Hatziandreu EJ, Patel KM, Davis RM. Trends in cigarette smoking in the United States: the changing influence of gender and race. JAMA. 1989;261:49-55.
29. Taylor HA, Mickel MC, Chaitman BR, Sopko G, Cutter GR, Rogers WJ. Long-term survival of African Americans in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol. 1997;29:358-364.
30. Eidelman RS, Lamas GA, Hennekens CH. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med. 2002;162:2033-2036.
31. Douglas JG, Bakris GL, Epstein M, et al. Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163(5):525-541.
32. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838.
33. Bakris GL, Williams M, Dworkin L, et al. for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36: 646-661.
34. Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int. 2001;59: 804-819.
35. Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet. 2000;355:253-259.
36. Lewis EJ, Hunsicker IG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
37. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703-713.
38. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA. 2001; 285:2719-2728.
39. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care. 2006;29(suppl 1):S4-S42.
40. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial (DCCT). Kidney Int. 1995;47:1703-1720.
41. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
42. Royce JM, Hymowitz N, Corbett K, et al. Smoking cessation factors among African Americans and Whites. COMMIT Research Group. Am J Public Health. 1993;83(2):220-226.
43. Mazas CA, Wetter DW. Smoking cessation interventions among African Americans: research needs. Cancer Control. 2003;10(5): 87-89.
44. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet. 1996;348:383.
45. Fraser SN, Spink KS. Examining the role of social support and group cohesion in exercise compliance. J Behav Med. 2002;25(3): 233-249.
46. Chen, MS, Jr. Informal care and the empowerment of minority communities: comparisons between the USA and the UK. Ethn Health. 1999;4(3):139-151.
47. National Center for Primary Care at the Morehouse School of Medicine. CRASH Course in Cultural Competency Skills. Available at: http://www.msm.edu/ NCPC/crash/ crash_powerpointpage.htm. Accessed on August 28, 2006.